S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
Warren Buffett's company dumps another 5 million shares of printer maker HP
The Strategic Gold Play You Haven't Heard About (Ad)
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Low PE Growth Stocks: Unlocking Investment Opportunities
The Strategic Gold Play You Haven't Heard About (Ad)
3 Reliable Growing Dividends Near Rock-Bottom Prices
Why Ralph Lauren Should Be On Your Holiday Wishlist
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: Wall Street futures inch higher as bond yields stabilize, oil prices slide
5 Short Squeeze Candidates With Catalysts For Rebounds
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
Warren Buffett's company dumps another 5 million shares of printer maker HP
The Strategic Gold Play You Haven't Heard About (Ad)
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Low PE Growth Stocks: Unlocking Investment Opportunities
The Strategic Gold Play You Haven't Heard About (Ad)
3 Reliable Growing Dividends Near Rock-Bottom Prices
Why Ralph Lauren Should Be On Your Holiday Wishlist
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: Wall Street futures inch higher as bond yields stabilize, oil prices slide
5 Short Squeeze Candidates With Catalysts For Rebounds
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
Warren Buffett's company dumps another 5 million shares of printer maker HP
The Strategic Gold Play You Haven't Heard About (Ad)
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Low PE Growth Stocks: Unlocking Investment Opportunities
The Strategic Gold Play You Haven't Heard About (Ad)
3 Reliable Growing Dividends Near Rock-Bottom Prices
Why Ralph Lauren Should Be On Your Holiday Wishlist
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: Wall Street futures inch higher as bond yields stabilize, oil prices slide
5 Short Squeeze Candidates With Catalysts For Rebounds
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
Warren Buffett's company dumps another 5 million shares of printer maker HP
The Strategic Gold Play You Haven't Heard About (Ad)
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Low PE Growth Stocks: Unlocking Investment Opportunities
The Strategic Gold Play You Haven't Heard About (Ad)
3 Reliable Growing Dividends Near Rock-Bottom Prices
Why Ralph Lauren Should Be On Your Holiday Wishlist
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: Wall Street futures inch higher as bond yields stabilize, oil prices slide
5 Short Squeeze Candidates With Catalysts For Rebounds
Lowest-Rated StocksLowest-RatedMost-Downgraded StocksMost-Downgraded
NASDAQ:SAGE

Sage Therapeutics (SAGE) Stock Forecast, Price & News

$20.08
+0.32 (+1.62%)
(As of 10/3/2023 ET)
Compare
Today's Range
$19.47
▼
$20.13
50-Day Range
$16.75
▼
$36.74
52-Week Range
$16.51
▼
$59.99
Volume
763,229 shs
Average Volume
1.54 million shs
Market Capitalization
$1.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.57
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Sage Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.15 Rating Score
Upside/​Downside
117.0% Upside
$43.57 Price Target
Short Interest
Bearish
18.51% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.46
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$37,280 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($8.93) to ($6.21) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

189th out of 965 stocks

Pharmaceutical Preparations Industry

66th out of 450 stocks

See Top Rated MarketRank™ Stocks Here

SAGE stock logo

About Sage Therapeutics (NASDAQ:SAGE) Stock

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; zuranolone, a neuroactive steroid, which has completed Phase III clinical trials for treating PPD and major depressive disorders, as well as is in Phase II clinical trials for treatment resistant depression, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. Its product pipeline also comprises SAGE-689 that is in Phase II clinical trial for treating acute GABA hypofunction; SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

SAGE Price History

SAGE Stock News Headlines

September 27, 2023 | benzinga.com
Bipolar Disorder Pipeline, Emerging Drugs, Clinical Trials, and FDA Approvals 2023 (Updated)
September 25, 2023 | americanbankingnews.com
Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Recommendation of "Hold" from Analysts
October 4, 2023 | Wall Street Fundamentals (Ad)
Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
September 15, 2023 | msn.com
Zuranolone: FDA-Approved Postpartum Depression Medication
September 13, 2023 | finance.yahoo.com
Sage Therapeutics reveals number of layoffs in Raleigh
September 13, 2023 | markets.businessinsider.com
Oppenheimer Reaffirms Their Hold Rating on SAGE Therapeutics (SAGE)
September 11, 2023 | markets.businessinsider.com
Scotiabank Sticks to Its Buy Rating for SAGE Therapeutics (SAGE)
September 8, 2023 | msn.com
B of A Securities Maintains Sage Therapeutics (SAGE) Neutral Recommendation
October 4, 2023 | Edge On The Street (Ad)
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
September 7, 2023 | msn.com
Mizuho Maintains Sage Therapeutics (SAGE) Neutral Recommendation
September 7, 2023 | msn.com
RBC Capital Maintains Sage Therapeutics (SAGE) Sector Perform Recommendation
September 7, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Phreesia (PHR) and SAGE Therapeutics (SAGE)
September 6, 2023 | finance.yahoo.com
Sage Therapeutics to Present at Upcoming September Investor Conferences
September 3, 2023 | msn.com
Sage Therapeutics fires 40% of staff after FDA rejected MDD bid
September 1, 2023 | msn.com
Sage Therapeutics to lay off about 40 percent of its workforce
September 1, 2023 | bizjournals.com
Sage Therapeutics cuts 40% of workforce following partial FDA rejection
September 1, 2023 | bizjournals.com
Five things: Pegasystems, Sage cuts jobs; Starry emerges; Sumner Tunnel opens, so who's on the T?
August 31, 2023 | finance.yahoo.com
Midday movers: Salesforce, Dollar General, Crowdstrike and more
August 31, 2023 | finance.yahoo.com
Sage cuts nearly half its staff in wake of partial FDA rejection
August 31, 2023 | finance.yahoo.com
FDA Documents Suggest Sage's Battle In Depression Will Be Trickier Than Expected
August 31, 2023 | marketwatch.com
Sage Therapeutics Cutting 40% of Staff in Restructuring >SAGE
August 31, 2023 | msn.com
Sage Therapeutics to lay off 40% of staff as it gears up for launch of post-partum depression treatment
August 25, 2023 | yahoo.com
Zuranolone is a triumph for PPD. But its implications for women’s health research are concerning
August 24, 2023 | finance.yahoo.com
Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month?
August 22, 2023 | businesswire.com
SAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating Sage Therapeutics, Inc. on Behalf of Sage Stockholders and Encourages Investors to Contact the Firm
August 19, 2023 | prnewswire.com
SAGE INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sage Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
August 14, 2023 | msn.com
Sage Therapeutics: Undeserving Selloff Presents A Buying Opportunity
See More Headlines
Receive SAGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SAGE Company Calendar

Last Earnings
8/07/2023
Today
10/04/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SAGE
CUSIP
N/A
CIK
1597553
Web
www.sagerx.com
Phone
(617) 299-8380
Fax
617-299-8379
Employees
689
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$43.57
High Stock Price Forecast
$294.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+117.0%
Consensus Rating
Hold
Rating Score (0-4)
2.15
Research Coverage
20 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($9.92)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-532,780,000.00
Net Margins
-5,704.03%
Pretax Margin
-5,704.03%
Return on Equity
-49.82%
Return on Assets
-45.99%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.99
Quick Ratio
10.99

Sales & Book Value

Annual Sales
$10.37 million
Price / Sales
115.93
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$21.05 per share
Price / Book
0.95

Miscellaneous

Outstanding Shares
59,884,000
Free Float
56,710,000
Market Cap
$1.20 billion
Optionable
Optionable
Beta
1.10
The Best High-Yield Dividend Stocks for 2023 Cover
The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Barry E. GreeneMr. Barry E. Greene (Age 60)
    Pres, CEO & Director
    Comp: $1.29M
  • Ms. Kimi E. Iguchi CPA (Age 61)
    CFO & Treasurer
    Comp: $665.37k
  • Ms. Anne Marie Cook Esq. (Age 61)
    Sr. VP, Gen. Counsel & Sec.
    Comp: $711.6k
  • Mr. Christopher Benecchi (Age 51)
    Chief Bus. Officer
    Comp: $703.76k
  • Dr. Laura Gault M.D.
    Ph.D., Chief Medical Officer
  • Mr. Matt Lasmanis
    Chief Technology & Innovation Officer
  • Mr. Mike Quirk
    Chief Scientific Officer
  • Helen Rubinstein
    Investor Relations Officer
  • Ms. Erin E. Lanciani (Age 54)
    Chief People & Experience Officer
  • Dr. Amy Schacterle Ph.D.
    Sr. VP of R&D Strategy and Bus. Management

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













SAGE Stock - Frequently Asked Questions

Should I buy or sell Sage Therapeutics stock right now?

20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last twelve months. There are currently 17 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.
View SAGE analyst ratings or view top-rated stocks.

What is Sage Therapeutics' stock price forecast for 2023?

20 brokerages have issued 12 month target prices for Sage Therapeutics' stock. Their SAGE share price forecasts range from $20.00 to $294.00. On average, they predict the company's share price to reach $43.57 in the next year. This suggests a possible upside of 117.0% from the stock's current price.
View analysts price targets for SAGE or view top-rated stocks among Wall Street analysts.

How have SAGE shares performed in 2023?

Sage Therapeutics' stock was trading at $38.14 on January 1st, 2023. Since then, SAGE stock has decreased by 47.4% and is now trading at $20.08.
View the best growth stocks for 2023 here.

When is Sage Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our SAGE earnings forecast.

How were Sage Therapeutics' earnings last quarter?

Sage Therapeutics, Inc. (NASDAQ:SAGE) issued its quarterly earnings results on Monday, August, 7th. The biopharmaceutical company reported ($2.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.55) by $0.13. The biopharmaceutical company had revenue of $2.47 million for the quarter, compared to analysts' expectations of $2.94 million. Sage Therapeutics had a negative trailing twelve-month return on equity of 49.82% and a negative net margin of 5,704.03%. The firm's revenue for the quarter was up 64.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($2.13) EPS.

What ETFs hold Sage Therapeutics' stock?

ETFs with the largest weight of Sage Therapeutics (NASDAQ:SAGE) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), Simplify Propel Opportunities ETF (SURI), ALPS Medical Breakthroughs ETF (SBIO) and Alpha Architect U.S. Quantitative Momentum ETF (QMOM).Invesco Dorsey Wright Healthcare Momentum ETF (PTH).

What other stocks do shareholders of Sage Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).

What is Sage Therapeutics' stock symbol?

Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

How do I buy shares of Sage Therapeutics?

Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sage Therapeutics' stock price today?

One share of SAGE stock can currently be purchased for approximately $20.08.

How much money does Sage Therapeutics make?

Sage Therapeutics (NASDAQ:SAGE) has a market capitalization of $1.20 billion and generates $10.37 million in revenue each year. The biopharmaceutical company earns $-532,780,000.00 in net income (profit) each year or ($9.92) on an earnings per share basis.

How many employees does Sage Therapeutics have?

The company employs 689 workers across the globe.

How can I contact Sage Therapeutics?

Sage Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The official website for the company is www.sagerx.com. The biopharmaceutical company can be reached via phone at (617) 299-8380, via email at ir@sagerx.com, or via fax at 617-299-8379.

This page (NASDAQ:SAGE) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -